|
Real-time Estimate
Other stock markets
|
5-day change | 1st Jan Change | ||
| 2.045 USD | -3.08% |
|
-7.88% | +44.01% |
| 01-23 | Top Midday Gainers | MT |
| 01-23 | Oppenheimer Initiates Coverage on Coherus BioSciences With Outperform Rating | MT |
| Capitalization | 255M 215M 197M 187M 347M 23.15B 358M 2.27B 906M 11.13B 956M 937M 39.1B | P/E ratio 2025 * |
-14.7x | P/E ratio 2026 * | -1.88x |
|---|---|---|---|---|---|
| Enterprise value | 255M 215M 197M 187M 347M 23.15B 358M 2.27B 906M 11.13B 956M 937M 39.1B | EV / Sales 2025 * |
5.87x | EV / Sales 2026 * | 2.68x |
| Free-Float |
95.98% | Yield 2025 * |
-
| Yield 2026 * | - |
Last Transcript: Coherus Oncology, Inc.
| 1 day | -3.08% | ||
| 1 week | -7.88% | ||
| Current month | -5.32% | ||
| 1 month | +23.94% | ||
| 3 months | +51.48% | ||
| 6 months | +132.31% | ||
| Current year | +44.01% |
| 1 week | 1.94 |  | 2.24 |
| 1 month | 1.51 | | 2.62 |
| Current year | 1.35 | | 2.62 |
| 1 year | 0.71 | | 2.62 |
| 3 years | 0.66 | | 8.65 |
| 5 years | 0.66 | | 19.32 |
| 10 years | 0.66 | | 31.98 |
| Manager | Title | Age | Since |
|---|---|---|---|
Denny Lanfear
CEO | Chief Executive Officer | 70 | 01/09/2010 |
Bryan Mcmichael
DFI | Director of Finance/CFO | 48 | 08/12/2023 |
Rosh Dias
CTO | Chief Tech/Sci/R&D Officer | - | 15/03/2022 |
| Director | Title | Age | Since |
|---|---|---|---|
Mats Wahlström
BRD | Director/Board Member | 71 | 01/01/2012 |
Denny Lanfear
CHM | Chairman | 70 | 01/09/2010 |
Ali Satvat
BRD | Director/Board Member | 48 | 01/05/2014 |
| Change | 5d. change | 1-year change | 3-years change | Capi.($) | ||
|---|---|---|---|---|---|---|
 | -3.08% | -7.88% | +84.23% | -74.53% | 255M | |
| -0.16% | -7.58% | +18.28% | +192.00% | 918B | |
| +0.95% | +2.69% | +54.21% | +47.94% | 574B | |
| -1.07% | +1.45% | +14.82% | +43.28% | 393B | |
| +1.62% | -1.05% | +23.80% | +27.79% | 366B | |
| +1.74% | +3.71% | +25.56% | +53.07% | 301B | |
| +4.62% | +7.41% | +27.48% | +29.73% | 300B | |
| +1.66% | +0.48% | +37.39% | +8.53% | 291B | |
| -2.62% | +0.67% | -48.90% | -38.29% | 223B | |
| -0.19% | -0.39% | +22.96% | +49.70% | 196B | |
| Average | +0.27% | +0.18% | +25.98% | +33.92% | 356.3B | |
| Weighted average by Cap. | +0.58% | +1.25% | +23.27% | +72.84% |
| 2025 * | 2026 * | |
|---|---|---|
| Net sales | 43.47M 36.64M 33.53M 31.86M 59.08M 3.95B 61.08M 387M 154M 1.9B 163M 160M 6.66B | 95.15M 80.19M 73.39M 69.73M 129M 8.63B 134M 846M 338M 4.15B 357M 350M 14.59B |
| Net income | -178M -150M -137M -131M -242M -16.16B -250M -1.58B -632M -7.77B -668M -654M -27.3B | -143M -121M -110M -105M -194M -12.98B -201M -1.27B -508M -6.24B -536M -525M -21.92B |
| Net Debt | - | - |
Employees
158
Sector
Pharmaceuticals
Calendar
| Date | Price | Change | Volume |
|---|---|---|---|
| 11/02/26 | 2.047 $ | -3.00% | 568,126 |
| 10/02/26 | 2.110 $ | +2.43% | 805,723 |
| 09/02/26 | 2.060 $ | -3.74% | 1,479,656 |
| 06/02/26 | 2.140 $ | +2.39% | 2,444,996 |
| 05/02/26 | 2.090 $ | -5.86% | 1,692,772 |
Sell
Buy
Mean consensus
BUY
Number of Analysts
6
Last Close Price
2.110USD
Average target price
6.750USD
Spread / Average Target
+219.91%
Quarterly revenue - Rate of surprise
- Stock Market
- Equities
- CHRS Stock
Select your edition
All financial news and data tailored to specific country editions
MarketScreener is also available in this country: United States.
Switch edition
Stay in the current country edition